Because SGLT2 inhibitors act on the kidney, and the amount of glucose excreted is closely dependent on the glomerular filtration rate (GFR), it can be anticipated that SGLT2 inhibitors will have a ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

SGLT2 inhibitors are a new family of agents ... Canagliflozin; eGFR Estimated glomerular filtration rate; FPG: Fasting plasma glucose; PPG: Post prandial glucose; SITA: Sitagliptin; TIIDM ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

Older adults had a lower risk for major adverse CV events than younger adults with SGLT2 inhibitors. Perspective from Sara Cromer, MD SGLT2 inhibitors confer greater risk reductions for major ...

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

Opens in a new tab or window Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors from 2014 to 2020. Real-world outcomes largely point to comparable ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

" Empagliflozin significantly reduced CI-AKI incidence in PCI patients by enhancing renal function markers, including eGFR ...

sodium-glucose transporter 2 (SGLT2) inhibitors — these reduce the amount of glucose reabsorbed by the kidneys, meaning that it is excreted in the urine. A meta-analysis, published in the ...